Published in Pharmacol Res Perspect on June 10, 2016
Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol Rev (2006) 6.75
Neurotransmitters and neuromodulators in the basal ganglia. Trends Neurosci (1990) 2.83
The basal ganglia. Curr Biol (2000) 2.64
Half a century of antipsychotics and still a central role for dopamine D2 receptors. Prog Neuropsychopharmacol Biol Psychiatry (2003) 2.18
Isolation and characterization of a dual-substrate phosphodiesterase gene family: PDE10A. Proc Natl Acad Sci U S A (1999) 2.10
Immunohistochemical localization of PDE10A in the rat brain. Brain Res (2003) 1.61
Immunohistochemical localization of phosphodiesterase 10A in multiple mammalian species. J Histochem Cytochem (2006) 1.60
Preclinical characterization of selective phosphodiesterase 10A inhibitors: a new therapeutic approach to the treatment of schizophrenia. J Pharmacol Exp Ther (2008) 1.60
Dopamine D(2) receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient. Biol Psychiatry (2001) 1.58
Distinct roles of PDE4 and PDE10A in the regulation of cAMP/PKA signaling in the striatum. J Neurosci (2008) 1.48
Extrapyramidal symptoms with atypical antipsychotics : incidence, prevention and management. Drug Saf (2005) 1.41
Striatum- and testis-specific phosphodiesterase PDE10A isolation and characterization of a rat PDE10A. Eur J Biochem (1999) 1.41
Cellular and subcellular localization of PDE10A, a striatum-enriched phosphodiesterase. Neuroscience (2006) 1.37
Isolation and characterization of PDE10A, a novel human 3', 5'-cyclic nucleotide phosphodiesterase. Gene (1999) 1.35
Phosphodiesterase 10A inhibitor activity in preclinical models of the positive, cognitive, and negative symptoms of schizophrenia. J Pharmacol Exp Ther (2009) 1.35
The conditioned avoidance response test re-evaluated: is it a sensitive test for the detection of potentially atypical antipsychotics? Neurosci Biobehav Rev (1999) 1.25
The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review. CNS Drugs (2014) 1.18
Comparison of dopamine receptor antagonists on hyperlocomotion induced by cocaine, amphetamine, MK-801 and the dopamine D1 agonist C-APB in mice. Psychopharmacology (Berl) (1999) 1.08
Catalepsy as a rodent model for detecting antipsychotic drugs with extrapyramidal side effect liability. Psychopharmacology (Berl) (1995) 1.06
Increased social interaction in mice deficient of the striatal medium spiny neuron-specific phosphodiesterase 10A2. J Neurochem (2007) 1.01
Subcellular localization of cyclic nucleotide phosphodiesterase type 10A variants, and alteration of the localization by cAMP-dependent protein kinase-dependent phosphorylation. J Biol Chem (2003) 0.99
Rapid identification of a novel small molecule phosphodiesterase 10A (PDE10A) tracer. J Med Chem (2012) 0.92
In vivo pharmacological characterization of TAK-063, a potent and selective phosphodiesterase 10A inhibitor with antipsychotic-like activity in rodents. J Pharmacol Exp Ther (2014) 0.90
The novel phosphodiesterase 10A inhibitor THPP-1 has antipsychotic-like effects in rat and improves cognition in rat and rhesus monkey. Neuropharmacology (2012) 0.89
Current schizophrenia drugs: efficacy and side effects. Expert Opin Pharmacother (2006) 0.87
Advanced research on dopamine signaling to develop drugs for the treatment of mental disorders: biochemical and behavioral profiles of phosphodiesterase inhibition in dopaminergic neurotransmission. J Pharmacol Sci (2010) 0.85
Characterization of the binding properties of T-773 as a PET radioligand for phosphodiesterase 10A. Nucl Med Biol (2014) 0.84
Effects of zotepine, haloperidol and clozapine on MK-801-induced stereotypy and locomotion in rats. J Neural Transm Gen Sect (1994) 0.83
Disturbed glucose metabolism among patients taking olanzapine and typical antipsychotics. Psychopharmacol Bull (2003) 0.83
PDE10A inhibitors stimulate or suppress motor behavior dependent on the relative activation state of the direct and indirect striatal output pathways. Pharmacol Res Perspect (2014) 0.78